STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial

While overall survival data remain immature, the results pointed to a favourable trend.

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial

Datroway wins US nod in aggressive breast cancer subtype

Clearance marks major shift beyond chemotherapy

WHO declares Ebola outbreak, Indians advised against travel to affected regions

No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease

AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%

The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Venus Remedies secures global approval for Plerixafor in Saudi Arabia

SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma